FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
2021
2020
2019
2018
21.17M
11.26M
28.32M
0
0
0
0
0
21.17M
11.26M
28.32M
0
51.88M
33.64M
46.67M
28.47M
28.75M
14.13M
31.39M
19.75M
23.13M
19.51M
15.28M
8.72M
0
0
0
0
23.13M
19.51M
15.28M
8.72M
651k
-3.23M
-1.25M
0
-30.71M
-22.39M
-22.5M
-28.47M
-941k
-3.23M
-1.6M
5.62M
-31.66M
-25.62M
-23.75M
-22.85M
-372k
-1k
-737k
0
-31.28M
-25.62M
-23.01M
-22.85M
-1.88
-9.69
-2.54
-0
-1.88
-9.69
-2.54
-0
16.65M
2.64M
9.07M
14.62B
16.65M
2.64M
9.07M
14.62B
-29.42M
-21.24M
-13.35M
-28.47M
2021
2020
2019
2018
-47.17M
-21.55M
-102.07M
-79.21M
-31.28M
-25.62M
-23.01M
-22.85M
0
0
0
0
0
0
0
0
-78.45M
-47.17M
-21.55M
-102.07M
-31.28M
-25.62M
80.52M
-22.85M
2021
2020
2019
2018
4.17M
3.57M
2.03M
2.32M
1.29M
1.14M
9.15M
288k
-658k
-730k
-127k
-1.97M
3.53M
3.16M
-6.99M
4M
2021
2020
2019
2018
-28k
10.61M
4.32M
0
14.93M
4.32M
0
0
14.9M
14.93M
4.32M
0
All figures are in USD.